Preveceutical Medical Inc · CSE:PREV
Preveceutical Medical — Investor Presentation (April 2026)
24 slides from Preveceutical Medical's investor presentation, April 2026
Slide 1: Corporate Presentation: Non-Addictive Endogenous, Opioid-Based Analgesics
CORPORATE PRESENTATION -NON-ADDICTIVE ENDOGENOUS, OPIOID- BASED ANALGESICS April 2026 CSE: PREV OTCQB: PRVCF FSE: 18H
Slide 2: Disclaimer
DISCLAIMER This presentation and its appendices (together the “Presentation”) have been prepared and delivered by PreveCeutical® Medical Inc. (“PreveCeutical” or the “Company”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H). The Presentation and its contents are strictly confidential and may not be reproduced
Slide 3: Corporate Overview
CORPORATE OVERVIEW Preventive health sciences company with corporate offices in Vancouver, Canada, and wholly owned subsidiary in Brisbane, Australia. Leveraging innovative science & technology to enhance natural products as novel targeted therapeutics in a diverse portfolio of R&D programs addressi
Slide 4: Corporate Overview: Opioid Crisis Facts and Figures
CORPORATE OVERVIEW OPIOID CRISIS – THE FACTS Since 1999, >600,000 people in the USA & Canada have died from an opioid overdose1 In addition, millions more became addicted or were seriously/irreversibly harmed Mortality rates in each country exceeds that of the worst of the HIV/AIDS epidemic. OPIOID
Slide 5: Non-Addictive Analgesic Peptides for Pain Management
NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT SELECTIVELY TARGETING THE KAPPA-OPIOID RECEPTOR Clinically available opioid analgesics primarily target the Mu-opioid (MOR) receptor while also hitting targets in the A panel of peptides was designed and evaluated in a central nervous system (CNS)
Slide 6: Four Stages of Discovery Through Preclinical Proof-of-Concept
NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT SELECTIVELY TARGETING THE KAPPA-OPIOID RECEPTOR The following four stages spanning drug discovery-thru-preclinical proof-of-concept studies have been successfully completed: STAGE STAGE STAGE STAGE 01 02 03 04 In silico design of Dynorphin Iterati
Slide 7: Stage 1: In Silico Design of Dynorphin Peptides
NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT SELECTIVELY TARGETING THE KAPPA-OPIOID RECEPTOR STAGE 1 COMPLETED STAGE 1: In silico design of Dynorphin (DYN)-based peptide fragments, and opioid receptor docking/affinity screening studies. › Using DYN1-7 as our model fragment, a library of >100
Slide 8: Stage 2: Peptide Synthesis and In Vitro Screening
NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT SELECTIVELY TARGETING THE KAPPA-OPIOID RECEPTOR STAGE 2 COMPLETED STAGE 2: Iterative design and synthesis of DYN fragment peptide libraries with in vitro screening of kappa-opioid receptor selectivity, and metabolic stability. › Top Panel: In vitr
Slide 9: Stage 3: Metabolically-Stabilized Peptide Libraries
NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT SELECTIVELY TARGETING THE KAPPA-OPIOID RECEPTOR STAGE 3 COMPLETED STAGE 3: Engineering of metabolically-stabilized DYN peptide libraries (linear and cyclised), retaining exquisite KOR-selectivity while displaying reduced desensitization, and biase
Slide 10: Stage 4: Rodent Model of Inflammatory Pain
NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT SELECTIVELY TARGETING THE KAPPA-OPIOID RECEPTOR STAGE 3 COMPLETED STAGE 4: Select peptides evaluated in a Freud’s Complete Adjuvant (FCA) rodent model of inflammatory pain, demonstrating analgesia com parable to the clinically used opiates. › In v
Slide 11: Completed Studies and Proposed Studies
NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT SELECTIVELY TARGETING THE KAPPA-OPIOID RECEPTOR COMPLETED STUDIES PROPOSED STUDIES WITH LINEAR & CYCLISED PEPTIDES › STAGE 1: In silico design of Dynorphin (DYN)-based peptide fragments and opioid receptor docking/affinity screening studies. › Tol
Slide 12: Non-Addictive Analgesic Project Patent Family
NON-ADDICTIVE ANALGESIC PROJECT PATENT FAMILY PATENT NAME COUNTRY FILLING DATE PUBLICATION DATE INTERNATIONAL 26.07.2018 31.01.2019 DISULFIDE BOND CONTAINING AUSTRALIA 15.12.2022 02.02.2023 COMPOUNDS AND USES THEREOF EUROPE 26.07.2018 03.06.2020 CANADA 26.07.2018 31.01.2019 USA 11.05.2023 11.05.2023
Slide 13: PreveCeutical Team
PREVECEUTICAL TEAM Stephen Van Deventer Mak Jawadekar PhD - Chairman and Chief Executive Officer – President, Chief Science Officer and Director Mr. Van Deventer is an experienced businessman Dr. Jawadekar completed his Ph.D. in Pharmaceutics at and corporate director. Specializing in international
Slide 14: PreveCeutical Team
PREVECEUTICAL TEAM Kathy Rokita CPA C. Evan Ballantyne – Director – Director Ms. Rokita is a finance, operations, and strategey-focused Mr. Ballantyne has extensive executive leadership experience and executive having extensive experience with large medical groups. has spent the last 20 years as a p
Slide 15: PreveCeutical Team
PREVECEUTICAL TEAM Raj Pruthi, MD, MHA, FACS Harry Parekh PhD, BSc Hons I - Director - Chief Research Officer Dr. Pruthi is a distinguished physician-scientist, executive leader Based at the University of Queensland’s (UQ) Pharmacy and board-level strategist with over 20 years of experience Australi
Slide 16: PreveCeutical Team
PREVECEUTICAL TEAM Francis Tavares, PhD Kamal Albarazanji – Chief Technology Officer - Director of Research Dr. Tavares has extensive experience in the preclinical Based at the University of Queensland’s (UQ) Pharmacy development of small molecule inhibitors in various target Australia Centre of Exc
Slide 17: PreveCeutical Team
PREVECEUTICAL TEAM Sydney Cole – Executive Assistant & Office Manager Ms. Cole has held Administration Support and trainer roles within the Hospitality Industry for seven years. Ms. Cole has also worked for a Venture Capital company for seven years as an executive assistant and office manager. From
Slide 18: PreveCeutical Australia Team
PREVECEUTICAL AUSTRALIA TEAM PreveCeutical® has established a wholly- owned subsidiary in Brisbane, Queensland, Australia, to bolster their research and development interests. The Australian team, which will be led by Stephen Van Deventer, the Chief Executive Officer, will work closely with Dr. Harr
Slide 19: Research Collaborators
RESEARCH COLLABORATORS Dr. Rakesh Veedu is leading the Precision Nucleic Professor Grant Ramm is currently the head of the Acids Theranostics Group, as a McCusker Research Hepatic Fibrosis Laboratory and Coordinator of the Fellow with the Perron Institute for Neurological and Cell and Molecular Biol
Slide 20: Research Collaborators
RESEARCH COLLABORATORS Dr. Ajit Shetty Aditya Bahl Dr. Shetty has extensive pharmaceutical experience Mr. Bahl brings over 20 years of experience in leading commercial and supply chain operations pharmaceutical marketing and clinical as well as significant educational background development and is k
Slide 21: Research Collaborators
RESEARCH COLLABORATORS Dr. Bryan Jones Stephen Glover Dr. Jones has more than 30 years of experience with Mr. Glover joins PreveCeutical as a Corporate biotech and specialty pharmaceutical companies Advisor, bringing multifaceted experience in Fortune with roles in product and business development.
Slide 22: Research Collaborators
RESEARCH COLLABORATORS Dr. Deepak Sampath Dr. Sampath will serve as a Corporate Advisor for PreveCeutical. He is the Senior VP, Head of Research at Ultragenyx, with previous experience at Pfizer and Genetech, along with several patents in the treatment of cancers. He has extensive experience in smal
Slide 23: Partners
PARTNERS THE UNIVERSITY ww D UMOULIN 0! OF QUEENSLAND MURDOCH [B) | BLACK a AUSTRALIA UNIVERSITY PERTH, WESTERN AUSTRALIA sefith:- MK Bae 222s grjffit cae IP Amplified RAS f PREVECEUTICAY
Slide 24: Please Contact
Stephen Van Deventer info@preveceutical.com PLEASE Investor Relations CONTACT ir@preveceutical.com 1 (604) 306-9669
PreveCeutical Medical — Investor Presentation (April 2026) on 6ix